BioHarvest Sciences Inc. Common Stock

AI-generated fair value estimate for this company.

Method: 10-year revenue-growth DCF starting from FY2025 actual revenue of $34.51M and FY2026 guidance midpoint of $45M (guided range $42-48M), with growth decelerating from ~30% to a 5% terminal rate and EBITDA margin ramping from roughly breakeven to a mature 16% by year 8-10, discounted at 14% (small-cap, high-volatility discount rate) with 3% terminal growth, plus net cash of $20.2M, over 22.67M shares outstanding.

Reasoning: BHST has real, fast-growing, diversified product/CDMO revenue (FY2025 revenue +37% YoY, Q1 2026 CDMO segment +135% YoY, VINIA consumer brand scaling) rather than being a pre-revenue biotech, so a revenue-growth DCF with a realistic margin ramp is workable and more rigorous than a pure multiple.